Literature DB >> 8580018

Resolution of hepatitis B virus-related membranoproliferative glomerulonephritis after orthotopic liver transplantation.

A Quan1, A Portale, S Foster, J Lavine.   

Abstract

The most well-described renal disease associated with hepatitis B virus (HBV) infection is membranous glomerulonephritis; membranoproliferative glomerulonephritis is described much less frequently. The course of HBV-associated renal disease after liver transplantation has not been described to date. We present a 15-year-old girl with HBV-associated membranoproliferative glomerulonephritis and end-stage liver disease, in whom, after cadaver liver transplantation, clinical and histological resolution of renal disease was observed. Resolution was associated with diminution of circulating HBV surface antigen levels.

Entities:  

Mesh:

Year:  1995        PMID: 8580018     DOI: 10.1007/bf00860947

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  15 in total

Review 1.  Immunopathogenetic mechanisms of hepatitis B virus-related glomerulopathy.

Authors:  Y Takekoshi; H Tochimaru; Y Nagata; N Itami
Journal:  Kidney Int Suppl       Date:  1991-12       Impact factor: 10.545

Review 2.  Clinical features and the natural course of hepatitis B virus-related glomerulopathy in adults.

Authors:  K N Lai; F M Lai
Journal:  Kidney Int Suppl       Date:  1991-12       Impact factor: 10.545

3.  Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane.

Authors:  B Combes; J Shorey; A Barrera; P Stastny; E H Eigenbrodt; A R Hull; N W Carter
Journal:  Lancet       Date:  1971-07-31       Impact factor: 79.321

4.  Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients.

Authors:  D Samuel; A Bismuth; D Mathieu; J L Arulnaden; M Reynes; J P Benhamou; C Brechot; H Bismuth
Journal:  Lancet       Date:  1991-04-06       Impact factor: 79.321

5.  Reversibility of hepatitis B virus-induced glomerulonephritis and chronic active hepatitis after spontaneous clearance of serum hepatitis B surface antigen.

Authors:  G L Knecht; F V Chisari
Journal:  Gastroenterology       Date:  1978-12       Impact factor: 22.682

6.  Hepatitis-B-associated glomerulonephritis: pathology, pathogenesis, and clinical course.

Authors:  V S Venkataseshan; K Lieberman; D U Kim; S N Thung; S Dikman; V D'Agati; M Susin; E Valderrama; B Gauthier; A Prakash
Journal:  Medicine (Baltimore)       Date:  1990-07       Impact factor: 1.889

7.  The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenaemia.

Authors:  K N Lai; J S Tam; H J Lin; F M Lai
Journal:  Nephron       Date:  1990       Impact factor: 2.847

8.  Hepatitis B surface antigenemia in North American children with membranous glomerulonephropathy. Southwest Pediatric Nephrology Study Group.

Authors: 
Journal:  J Pediatr       Date:  1985-04       Impact factor: 4.406

9.  Childhood membranoproliferative glomerulonephritis type I: limited steroid therapy.

Authors:  D M Ford; D M Briscoe; P F Shanley; G M Lum
Journal:  Kidney Int       Date:  1992-06       Impact factor: 10.612

10.  Membranous nephropathy in 52 hepatitis B surface antigen (HBsAg) carrier children in Taiwan.

Authors:  H C Hsu; C Y Wu; C Y Lin; G J Lin; C H Chen; F Y Huang
Journal:  Kidney Int       Date:  1989-12       Impact factor: 10.612

View more
  2 in total

Review 1.  Extrahepatic manifestations of chronic viral hepatitis.

Authors:  N T Pyrsopoulos; K R Reddy
Journal:  Curr Gastroenterol Rep       Date:  2001-02

2.  Successful entecavir plus prednisolone treatment for hepatitis B virus-associated membranoproliferative glomerulonephritis: A case report.

Authors:  Hiroshi Kataoka; Toshio Mochizuki; Taro Akihisa; Kentaro Kawasoe; Keiko Kawachi; Shiho Makabe; Anri Sawada; Shun Manabe; Masayo Sato; Nobuyuki Amemiya; Michihiro Mitobe; Takafumi Akanuma; Yasuko Ito; Takahiro Inoue; Tomo Suzuki; Katsuomi Matsui; Takahito Moriyama; Shigeru Horita; Mamiko Ohara; Kazuho Honda; Kosaku Nitta
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.